Neupogen (Filgrastim)

Filgrastim mimics the natural granulocyte colony‑stimulating factor. It binds to specific receptors on bone‑marrow progenitor cells, activating intracellular pathways that drive the proliferation and maturation of neutrophil precursors. The result is a rapid increase in circulating neutrophils, enhancing the body’s innate defence against infection.

The dose of Neupogen is individualized by the treating physician based on the patient’s clinical condition, type of chemotherapy, body weight, and laboratory parameters. Dosage regimens are not standardized in public information, and prescribers adjust the amount and frequency to achieve the desired neutrophil response while minimizing side effects.

Limited clinical data exist for filgrastim use in pregnancy and lactation. It should only be administered when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers must evaluate each case carefully and discuss potential risks with the patient.

To request Neupogen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any necessary import documentation.

Neupogen (filgrastim) is a short‑acting G‑CSF that requires daily administration, whereas pegylated forms such as pegfilgrastim have a longer half‑life and are given as a single dose per chemotherapy cycle. Both agents increase neutrophil counts, but the choice depends on treatment schedule, patient convenience, and cost considerations.

Neupogen must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. If the product reaches room temperature, it should be used promptly according to the manufacturer’s guidance.

Neupogen is supplied as a sterile solution for injection and can be given either intravenously or subcutaneously. Administration is performed by a qualified healthcare professional, typically once daily until the desired neutrophil count is achieved or as directed by the prescribing clinician.

Serious adverse events include splenic rupture, severe allergic reactions such as anaphylaxis, and acute respiratory distress syndrome. Patients should be monitored for sudden abdominal pain, difficulty breathing, rash, swelling, or any signs of severe infection, and medical attention should be sought immediately if these occur.

Neupogen is contraindicated in individuals with a known hypersensitivity to filgrastim or any of its excipients. Caution is also advised for patients with active, uncontrolled infections, severe splenomegaly, or those receiving other colony‑stimulating factors, as these conditions may increase the risk of complications.